Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpe2U study of genotype- and phenotype-guided fluoropyrimidine dose individualization
NL-OMON49970Not yet recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of capecitabine and fluorouracil in breast cancer, colorectal cancer (CRC) and gastric cancer (GC) (4 arms), sponsored by Netherlands Cancer Institute. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
capecitabinefluorouracil
03
Conditions
breast cancercolorectal cancer (CRC)gastric cancer (GC)
Beyond the preview
Go deeper on NL-OMON49970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49970.